ENSG00000223804 and cancer: In contrast to aspirin, the small molecule PolI inhibitor CX5461, which has shown considerable promise as an anti-cancer therapy and is currently in clinical trials for hematologic malignancies and triple negative breast cancer [82,92,93], had no effect on NF-κB signaling.